Peripheral Artery Disease Is Associated with a Deficiency of Erythrocyte Membrane n‐3 Polyunsaturated Fatty Acids
Authors:
- Joel L. RamirezJRJoel L. Ramirez
- Greg J. ZahnerGZGreg J. Zahner
- Kimberly A. SpauldingKSKimberly A. Spaulding
- Sukaynah A. KhetaniSKSukaynah A. Khetani
- Nancy K. HillsNHNancy K. Hills
- Warren J. GasperWGWarren J. Gasper
- William S. HarrisWHWilliam S. Harris
- Beth E. CohenBCBeth E. Cohen
- S. Marlene GrenonSGS. Marlene Grenon
Abstract
Population‐based data suggest that individuals who consume large dietary amounts of n‐3 polyunsaturated fatty acids (PUFA) have lower odds of peripheral artery disease (PAD); however, clinical studies examining n‐3 PUFA levels in patients with PAD are sparse. The objective of this study is to compare erythrocyte membrane fatty acid (FA) content between patients with PAD and controls. We conducted a cross‐sectional study of 179 vascular surgery outpatients (controls, 34; PAD, 145). A blood sample was drawn and the erythrocyte FA content was assayed using capillary gas chromatography. We calculated the ratio of the n‐3 PUFA eicosapentaenoic acid (EPA) to the n‐6 PUFA arachidonic acid (ARA) as well as the omega‐3 index (O3I), a measure of erythrocyte content of the n‐3 PUFA, EPA, and docosahexaenoic acid (DHA), expressed as a percentage of total erythrocyte FA. Compared with controls, patients with PAD smoked more and were more likely to have hypertension and hyperlipidemia (p < 0.05). Patients with PAD had a lower mean O3I (5.0 ± 1.7% vs 6.0 ± 1.6%, p < 0.001) and EPA:ARA ratio (0.04 ± 0.02 vs 0.05 ± 0.05, p < 0.001), but greater mean total saturated fats (39.5 ± 2.5% vs 38.5 ± 2.6%, p = 0.01). After adjusting for several patient characteristics, comorbidities, and medications, an absolute decrease of 1% in the O3I was associated with 39% greater odds of PAD (odds ratio [OR] 1.39, 95% confidence interval [CI] 1.03–1.86, and p = 0.03). PAD was associated with a deficiency of erythrocyte n‐3 PUFA, a lower EPA:ARA ratio, and greater mean total saturated fats. These alterations in FA content may be involved in the pathogenesis or development of poor outcomes in PAD.Keywords
Funding Information
- National Center for Advancing Translational Sciences
- National Institutes of Health
- American Heart Association
- Northern California Institute for Research and Education
- National Center for Research Resources (KL2‐RR024130)
- National Heart, Lung, and Blood Institute (K23‐HL122446‐01)
This publication has 52 references indexed in Scilit:
- Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart StudyJournal of Clinical Lipidology, 2018
- The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studiesAtherosclerosis, 2017
- Which has the stronger impact on coronary artery disease, eicosapentaenoic acid or docosahexaenoic acid?Hypertension Research, 2016
- Association between n-3 polyunsaturated fatty acid content of red blood cells and inflammatory biomarkers in patients with peripheral artery diseaseJournal of Vascular Surgery, 2013
- Deciphering the role of n-3 polyunsaturated fatty acid-derived lipid mediators in health and diseaseProceedings of the Nutrition Society, 2013
- Relation of omega-3 fatty acid and C-reactive protein to peripheral artery disease in patients with coronary artery diseaseHeart and Vessels, 2013
- Omega-3 Fatty Acids and Cardiovascular DiseaseJACC, 2011
- Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsisNature, 2009
- Intakes of long-chain n–3 polyunsaturated fatty acids and fish in relation to measurements of subclinical atherosclerosisThe American Journal of Clinical Nutrition, 2008
- 15-epi-lipoxin A4–mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute InflammationJournal of Experimental Medicine, 2004